Supported in part by these results, ReCode Therapeutics conducted a Phase 1 double-blind, placebo-controlled single ascending dose study (NCT05737485) in healthy subjects and an open-label single ascending dose study in individuals with PCD caused by DNAI1 mutations to evaluate the safety and tolerability of inhaled RCT1100, a DNAI1 mRNA-based therapeutic delivered by SORT-LNPs. Here, DNAI1 is linked to primary ciliary dyskinesia.